Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides

[1]  T. Krahn,et al.  Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study , 2010, Cardiovascular diabetology.

[2]  K. Berneis,et al.  Pre‐clinical diabetic cardiomyopathy: prevalence, screening, and outcome , 2010, European journal of heart failure.

[3]  M. Dorkhan,et al.  Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes , 2010, Vascular health and risk management.

[4]  D. J. Veldhuisen,et al.  Neurohormonal profile of patients with heart failure and diabetes , 2010, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[5]  L. Groop,et al.  Brain natriuretic peptide is related to diastolic dysfunction whereas urinary albumin excretion rate is related to left ventricular mass in asymptomatic type 2 diabetes patients , 2010, Cardiovascular diabetology.

[6]  I. Coma-Canella,et al.  Echocardiographic findings and NT-proBNP level in type-2 diabetic patients with and without ischemic heart disease. , 2009, Revista espanola de cardiologia.

[7]  M. Gheorghiade,et al.  The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. , 2009, Journal of cardiac failure.

[8]  M. Penco,et al.  Accuracy of N-terminal pro-brain natriuretic peptide in the identification of left ventricular dysfunction in high-risk asymptomatic patients , 2009, Journal of cardiovascular medicine.

[9]  P. Valensi,et al.  B-type natriuretic peptide, a marker of asymptomatic left ventricular dysfunction in type 2 diabetic patients. , 2008, Diabetes & metabolism.

[10]  Hans L Hillege,et al.  Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). , 2008, Archives of internal medicine.

[11]  C. O'connor,et al.  Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. , 2007, JAMA.

[12]  Moon-Kyu Lee,et al.  N-terminal pro-brain natriuretic peptide (NT-proBNP) in Type 2 diabetes with left ventricular dysfunction. , 2007, Diabetes research and clinical practice.

[13]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[14]  A. Morris,et al.  B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetes , 2005, Heart.

[15]  B. Waeber,et al.  Increased plasma levels of N-terminal brain natriuretic peptide (NT-proBNP) in type 2 diabetic patients with vascular complications. , 2005, Diabetes & metabolism.

[16]  C. Gullion,et al.  The incidence of congestive heart failure in type 2 diabetes: an update. , 2004, Diabetes care.

[17]  Julio E. Pérez,et al.  Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. , 2004, The American journal of cardiology.

[18]  Douglas W Mahoney,et al.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.

[19]  R. Eckel,et al.  Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. , 2002, Circulation.

[20]  M. Drazner,et al.  Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. , 2001, Journal of the American College of Cardiology.

[21]  B V Howard,et al.  The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. , 2001, Journal of the American College of Cardiology.

[22]  F. Maklady,et al.  Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. , 2001, The American journal of cardiology.

[23]  B. Capaldo,et al.  Diastolic Dysfunction in Patients with Non‐insulin‐dependent Diabetes Mellitus of Short Duration , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[24]  F. Rengo,et al.  Left ventricular diastolic filling in diabetes mellitus with and without hypertension. , 1995, American journal of hypertension.

[25]  D. Levy,et al.  Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). , 1991, The American journal of cardiology.

[26]  J. Laragh,et al.  Standardization of M-mode echocardiographic left ventricular anatomic measurements. , 1984, Journal of the American College of Cardiology.

[27]  P. Weeke,et al.  Diabetes is associated with impaired myocardial performance in patients without significant coronary artery disease. , 2010, Cardiovascular Diabetology.

[28]  U. Görmüş,et al.  Serum N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) and homocysteine levels in type 2 diabetic patients with asymptomatic left ventricular diastolic dysfunction. , 2010, Diabetes research and clinical practice.

[29]  S. Schinner.  Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .

[30]  R. Valle,et al.  The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[31]  P. Poirier,et al.  Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. , 2001, Diabetes care.

[32]  J. Menzin,et al.  Potential short-term economic benefits of improved glycemic control: a managed care perspective. , 2001, Diabetes care.